JW Pharmaceutical Corporation (KRX:001065)
South Korea
· Delayed Price · Currency is KRW 29,500
+2,250 (8.26%)
At close: Dec 5, 2025
JW Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 764,208 | 719,376 | 748,527 | 684,351 | 606,585 | 547,336 | Upgrade
|
| Other Revenue | - | -0 | -0 | - | - | - | Upgrade
|
| Revenue | 764,208 | 719,376 | 748,527 | 684,351 | 606,585 | 547,336 | Upgrade
|
| Revenue Growth (YoY) | 3.76% | -3.89% | 9.38% | 12.82% | 10.82% | 7.04% | Upgrade
|
| Cost of Revenue | 411,754 | 395,878 | 412,984 | 396,397 | 372,209 | 369,810 | Upgrade
|
| Gross Profit | 352,455 | 323,498 | 335,542 | 287,955 | 234,376 | 177,526 | Upgrade
|
| Selling, General & Admin | 216,708 | 210,610 | 204,728 | 182,652 | 171,220 | 149,035 | Upgrade
|
| Research & Development | 41,379 | 36,237 | 33,671 | 33,736 | 19,884 | 22,943 | Upgrade
|
| Operating Expenses | 255,144 | 240,766 | 238,911 | 227,464 | 203,528 | 178,849 | Upgrade
|
| Operating Income | 97,310 | 82,733 | 96,631 | 60,490 | 30,848 | -1,323 | Upgrade
|
| Interest Expense | -10,033 | -10,033 | -12,562 | -9,387 | -7,337 | -7,587 | Upgrade
|
| Interest & Investment Income | 4,962 | 4,962 | 6,322 | 5,814 | 1,981 | 632.79 | Upgrade
|
| Earnings From Equity Investments | 1,684 | 1,387 | 621.06 | -955.41 | -1,149 | -1,924 | Upgrade
|
| Currency Exchange Gain (Loss) | 1,087 | 1,087 | -1,817 | -2,300 | -925.96 | -2,214 | Upgrade
|
| Other Non Operating Income (Expenses) | -5,054 | 2,253 | -36,102 | 5,425 | -1,191 | -777.66 | Upgrade
|
| EBT Excluding Unusual Items | 89,957 | 82,390 | 53,095 | 59,088 | 22,227 | -13,193 | Upgrade
|
| Gain (Loss) on Sale of Investments | 790.9 | 790.9 | 2,830 | -8,908 | -646.8 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 464.91 | 464.91 | -1,088 | 3.28 | -1,048 | -12.24 | Upgrade
|
| Asset Writedown | -1,476 | -1,476 | - | -4,821 | - | - | Upgrade
|
| Other Unusual Items | 249.74 | 249.74 | - | - | - | - | Upgrade
|
| Pretax Income | 89,987 | 82,420 | 54,836 | 45,362 | 20,533 | -13,205 | Upgrade
|
| Income Tax Expense | 27,199 | 17,379 | 16,406 | 15,509 | 21,974 | 2,070 | Upgrade
|
| Earnings From Continuing Operations | 62,788 | 65,040 | 38,430 | 29,853 | -1,441 | -15,275 | Upgrade
|
| Minority Interest in Earnings | - | - | -1,424 | 2,039 | 473.6 | 34.19 | Upgrade
|
| Net Income | 62,788 | 65,040 | 37,006 | 31,892 | -967.85 | -15,241 | Upgrade
|
| Preferred Dividends & Other Adjustments | 4,259 | 4,259 | - | - | - | - | Upgrade
|
| Net Income to Common | 58,529 | 60,781 | 37,006 | 31,892 | -967.85 | -15,241 | Upgrade
|
| Net Income Growth | -14.47% | 75.75% | 16.04% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 23 | 23 | 24 | 23 | 23 | 23 | Upgrade
|
| Shares Outstanding (Diluted) | 23 | 23 | 24 | 23 | 23 | 23 | Upgrade
|
| Shares Change (YoY) | -6.67% | -2.01% | 2.49% | 0.07% | -0.05% | 0.04% | Upgrade
|
| EPS (Basic) | 2533.07 | 2605.86 | 1554.67 | 1373.14 | -41.70 | -656.37 | Upgrade
|
| EPS (Diluted) | 2533.07 | 2605.86 | 1554.67 | 1373.14 | -41.70 | -656.37 | Upgrade
|
| EPS Growth | -14.58% | 67.62% | 13.22% | - | - | - | Upgrade
|
| Free Cash Flow | 78,024 | 71,079 | 59,871 | 46,845 | 10,657 | 50,667 | Upgrade
|
| Free Cash Flow Per Share | 3376.80 | 3047.37 | 2515.25 | 2016.97 | 459.20 | 2182.01 | Upgrade
|
| Dividend Per Share | 450.000 | 450.000 | - | - | - | - | Upgrade
|
| Gross Margin | 46.12% | 44.97% | 44.83% | 42.08% | 38.64% | 32.44% | Upgrade
|
| Operating Margin | 12.73% | 11.50% | 12.91% | 8.84% | 5.08% | -0.24% | Upgrade
|
| Profit Margin | 7.66% | 8.45% | 4.94% | 4.66% | -0.16% | -2.79% | Upgrade
|
| Free Cash Flow Margin | 10.21% | 9.88% | 8.00% | 6.84% | 1.76% | 9.26% | Upgrade
|
| EBITDA | 116,049 | 101,834 | 119,206 | 77,327 | 46,960 | 19,365 | Upgrade
|
| EBITDA Margin | 15.19% | 14.16% | 15.93% | 11.30% | 7.74% | 3.54% | Upgrade
|
| D&A For EBITDA | 18,738 | 19,101 | 22,575 | 16,836 | 16,112 | 20,688 | Upgrade
|
| EBIT | 97,310 | 82,733 | 96,631 | 60,490 | 30,848 | -1,323 | Upgrade
|
| EBIT Margin | 12.73% | 11.50% | 12.91% | 8.84% | 5.08% | -0.24% | Upgrade
|
| Effective Tax Rate | 30.23% | 21.09% | 29.92% | 34.19% | 107.02% | - | Upgrade
|
| Advertising Expenses | - | 24,252 | 22,690 | 22,673 | 18,416 | 15,067 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.